VIMTALABSNSEVIMTA LABS LIMITED· PharmaceuticalsMediumNeutral
Announced Mon, 20 Jul · 15:22 IST

Vimta Labs Q1 FY27 Investor Presentation: Revenue up 13.7%, PAT at Rs 210 Mn

Investor Communications View source PDF

VIMTALABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+7.9%1-day move
₹558.00
prior close
₹530.45
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.5+7.9+4.4+1.6+1.8+5.6
Up moveDown movePending
AI summary

Vimta Labs shared Q1 FY27 investor presentation. Total income rose 13.7% YoY to Rs 1,129 Mn. EBITDA grew 16% YoY to Rs 411 Mn with 36.4% margin. PAT up 11.1% YoY to Rs 210 Mn (18.6% margin). EPS at Rs 4.7. CAPEX of Rs 180 Mn. FY22 to FY26 revenue CAGR at 17% and EBITDA at 16.2%. Margins expanded from 29% to 36% over five years. Plans include capacity expansion and new market entry across pharma, food, and electronics testing.

Likely market impact

Strong Q1 with double-digit growth in revenue and profit; consistent margin expansion and capacity plans signal positive outlook.